Caroline Schnakers, who carried out the research with Laureys, told CNN that one probable reason for the high rate of misdiagnosis is that doctors often base their diagnosis on observations of a patient's behavior, rather than assessing patients using standardized tests.
In a clinical trial conducted in Russia, dimebon improved the ability of patients with Alzheimer's disease on a standardized test used to measure disease severity.